Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (101-110 of 187) with videos related to

Pageof 19
Sort By:
Hematological Oncology|September 26, 2020
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter seriesAlessandra Iurlo, Francesca Palandri, Elena Maria Elli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2009
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7Alessandra Vultaggio, Francesca Nencini, Paul M Fitch, et al.
Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Blood|August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Pageof 19

Showing results (101-110 of 187) with videos related to

Sort By:
Pageof 19
Hematological Oncology|September 26, 2020
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter seriesAlessandra Iurlo, Francesca Palandri, Elena Maria Elli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2009
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7Alessandra Vultaggio, Francesca Nencini, Paul M Fitch, et al.
Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Blood|August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Pageof 19